Our findings revealed that the high expression of PBX4 in glioblastoma was correlated with a worse outcome for PD1 immunotherapy, while melanoma patients with a high expression of PBX4 could obtain clinical benefits from ICB therapy and prolong survival time. This evidence concerns the gene PBX4 and melanoma.